Fentanyl sublingual - Sosei
Alternative Names: AD-923; SGX-2001; SRSS-001Latest Information Update: 31 Dec 2021
At a glance
- Originator Sosei R&D
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Cancer pain
Most Recent Events
- 08 Oct 2009 Fentanyl sublingual (AD 923), as well as device for its administration, are licensed to Pharmasol
- 26 Dec 2008 Sosei reacquires commercialisation rights for fentanyl sublingual (AD 923) from Mundipharma
- 10 May 2008 Final pharmacokinetics data from a phase I trial in healthy volunteers presented at the 27th Annual Scientific Meeting of the American Pain Society (APS-2008)